Search Within

Kelly Fitzgerald

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (3)
  2. Research Letter (1)
Groups
  1. Body Imaging Service (4)
  2. Department of Medicine (4)
  3. GME, Medicine (4)
  4. Genitourinary Oncology Service (4)
  5. Graduate Medical Education (4)
  6. Hematologic Malignancies, Division of (4)

More Groups

People
  1. Andrea Knezevic (4)
  2. Chung-Han Lee (4)
  3. Cihan Duzgol (4)
  4. Darren Feldman (4)
  5. David Aggen (4)
  6. Maria Carlo (4)

More People

Years
  1. 2023 (3)
  2. 2022 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Cancer Research (1)
  3. European Urology (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. American Association for Cancer Research (1)
  3. Elsevier Science, Inc. (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Jacobi, R.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save